Pulmonary function test in patients with idiopathic pulmonary fibrosis: data from the National Registry for Moscow and Moscow region

The purpose of the work was to evaluate the frequency and severity of lung functional disorders, the relationship between respiratory function (RF) and clinical symptoms in patients with idiopathic pulmonary fibrosis (IPF). Materials and Methods. The National Registry registered IPF patients (n = 127; 90 (71%) men, 37 (29%) women; average age 69.5 ± 8.5 years), by March 2019 lived in Moscow and Moscow region; at the time of inclusion in the register the duration of the disease was 3.3 ± 3.1 years (22 (17%) < 1 year). The diagnosis of IPF is based on the clinical picture of the disease, the results of high-resolution computed tomography and/or histological examination of the material obtained by surgical lung biopsy. The data of the complex RF examination (spirometry, Body plethysmography, lung diffusion capacity by carbon monoxide – DL_CO), 6-minute walking test (6-MWT) and dyspnea evaluation according to the modified dyspnea scale (Modified Medical Research Council – mMRC) at the moment of inclusion in the register are analyzed. Results. Average value of forced vital capacity (FVC) was 78 ± 22% debt, ratio of forced expiratory volume for 1 s/FVC – 83 ± 9%, total lung capacity (TLC) – 77 ± 17% debt, DL_CO – 47 ± 18% debt. DL_CO, TLC, FVC were reduced in 97.5, 63 and 59% of patients respectively. In patients with a disease duration of less than 1 year, DL_CO was significantly higher than that of less than 1 year. The median distance covered by the 6-MWT was 317.5 m, dyspnea according to the mMRC scale – 2 points. Statistically significant correlations between RF values and shortness of breath, tolerance to physical activity have been revealed. Conclusion. In patients with IPF, included in the National Register, restrictive disorders of pulmonary ventilation were detected in the majority of cases, reduced DL_CO – in 97.5%. Statistically significant higher DL_CO values are noted for a disease duration of less than 1 year.

idiopathic pulmonary fibrosis, pulmonary function test, tolerance to the physical activity, shortness of breath

1. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines]. Pul'monologiya. 2016; 26 (4): 399–419. DOI: 10.18093/0869-0189-2016-26-4-399-419 (in Russian).

2. Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/ JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018; 198 (5): e44–68. DOI: 10.1164/rccm.2018071255ST.

3. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001; 134 (2): 136–151. DOI: 10.7326/0003-4819-134-2-200101160-00015.

4. Maher T.M. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr. Opin. Pulm. Med. 2013; 19 (5): 460–465. DOI: 10.1097/MCP.0b013e328363f4b7.

5. Shimbori C., Gauldie J., Kolb M. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr. Opin. Pulm. Med. 2013; 19 (5): 446–452. DOI: 10.1097/MCP.0b013e328363f4de.

6. Chuchalin A.G., Aisanov Z.R., Chikina S.Yu. et al. [Federal guidelines of Russian Respiratory Society on spirometry]. Pul'monologiya. 2014; 6: 11–23 (in Russian).

7. Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338. DOI: 10.1183/09031936.05.00034805.

8. Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26 (3): 511–522. DOI: 10.1183/09031936.05.00035005.

9. Macintyre N., Crapo R.O., Viegi G. et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 2005; 26 (4): 720–735. DOI: 10.1183/09031936.05.00034905.

10. Holland A.E., Spruit M.A., Troosters T. et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur. Respir. J. 2014; 44 (6): 1428–1446. DOI: 10.1183/09031936.00150314.

11. Lama V.N., Flaherty K.R., Toews G.B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168 (9): 1084–1090. DOI: 10.1164/rccm.200302-219OC.

12. Enright P.L., Sherrill D.L. Reference equations for the sixminute walk in healthy adults. Am. J. Respir. Crit. Care Med. 1998; 158 (5, Pt 1): 1384–1387. DOI: 10.1164/ajrccm.158.5.9710086.

13. Jegal Y., Kim D.S., Shim T.S. et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171 (6): 639–644. DOI: 10.1164/rccm.200403-331OC.

14. Flaherty K.R., Mumford J.A., Murray S. et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168 (5): 543–548. DOI: 10.1164/rccm.200209-1112OC.

15. Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168(5): 538–542. DOI: 10.1164/rccm.200211-1311OC.

16. Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157 (1): 199–203. DOI: 10.1164/ajrccm.157.1.9704130.

17. Daniil Z.D., Gilchrist F.C., Nicholson A.G. et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1999; 160 (3): 899–905. DOI: 10.1164/ajrccm.160.3.9903021.

18. Latsi P.I., du Bois R.M., Nicholson A.G. et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am. J. Respir. Crit. Care Med. 2003; 168 (5): 531–537. DOI: 10.1164/rccm.200210-1245OC.

19. Hyldgaard C., Hilberg O., Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014; 108 (4): 647–653. DOI: 10.1016/j.rmed.2014.01.008.

20. Kaunisto J., Kelloniemi K., Sutinen E. et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm. Med. 2015; 15: 92. DOI: 10.1186/s12890-015-0074-3.

21. Doubková M., Švancara J., Svoboda M. et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin. Respir. J. 2018; 12 (4): 1526–1535. DOI: 10.1111/crj.12700.

22. Wuyts W.A., Dahlqvist C., Slabbynck H. et al. Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Br. Med. J. Open Respir. Res. 2018; 5 (1): e000331. DOI: 10.1136/bmjresp-2018-000331.

23. Guler S., Zumstein P., Berezowska S. et al. Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. Swiss Med. Wkly. 2018; 148: w14577. DOI: 10.4414/smw.2018.14577.

24. Jo H.E., Glaspole I., Grainge C. et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur. Respir. J. 2017; 49 (2): pii: 1601592. DOI: 10.1183/13993003.01592-2016.

25. Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46 (1): 186–196. DOI: 10.1183/09031936.00217614.

26. Ferrara G., Carlson L., Palm A. et al. Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry. Eur. Clin. Respir. J. 2016; 3 (1): 31090. DOI: 10.3402/ecrj.v3.31090.

27. Jankowich M.D., Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung. 2010; 188 (5): 365–373. DOI: 10.1007/s00408-010-9251-6.

28. Wells A.U., King A.D., Rubens M.B. et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am. J. Respir. Crit. Care Med. 1997; 155 (4): 1367–1375. DOI: 10.1164/ajrccm.155.4.9105081.

29. Xaubet A., Agusti C., Luburich P. et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 158 (2): 431–436. DOI: 10.1164/ajrccm.158.2.9709008.

30. Isaac B.T., Thangakunam B., Cherian R.A., Christopher D.J. The correlation of symptoms, pulmonary function tests and exercise testing with high-resolution computed tomography in patients with idiopathic interstitial pneumonia in a tertiary care hospital in South India. Lung India. 2015; 32 (6): 584–588. DOI: 10.4103/0970-2113.168131.